About NovoCure Limited
https://www.novocure.comNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China.
CEO
Frank Leonard
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 156
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Piper Sandler
Overweight
Wells Fargo
Equal Weight
JP Morgan
Neutral
Wedbush
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:16.77M
Value:$230.92M
BLACKROCK, INC.
Shares:13.95M
Value:$192.06M
BLACKROCK INC.
Shares:12.13M
Value:$167.06M
Summary
Showing Top 3 of 323
About NovoCure Limited
https://www.novocure.comNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $167.2M ▲ | $158.5M ▲ | $-37.27M ▲ | -22.29% ▲ | $-0.33 ▲ | $-26.36M ▲ |
| Q2-2025 | $158.81M ▲ | $156.85M ▲ | $-40.14M ▼ | -25.28% ▼ | $-0.36 ▼ | $-36.08M ▼ |
| Q1-2025 | $154.99M ▼ | $154.34M ▼ | $-34.32M ▲ | -22.14% ▲ | $-0.31 ▲ | $-34.54M ▼ |
| Q4-2024 | $161.27M ▲ | $191.1M ▲ | $-65.92M ▼ | -40.88% ▼ | $-0.61 ▼ | $-10.52M ▲ |
| Q3-2024 | $155.09M | $151.81M | $-30.57M | -19.71% | $-0.28 | $-29.63M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.04B ▲ | $1.36B ▲ | $1.02B ▲ | $341.33M ▼ |
| Q2-2025 | $911.52M ▼ | $1.25B ▼ | $896.43M ▲ | $349.44M ▼ |
| Q1-2025 | $931.28M ▼ | $1.25B ▲ | $886.85M ▲ | $361.96M ▲ |
| Q4-2024 | $959.87M ▼ | $1.24B ▲ | $880.61M ▲ | $360.18M ▼ |
| Q3-2024 | $963.67M | $1.22B | $861.21M | $360.78M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-37.27M ▲ | $20.57M ▲ | $71.44M ▲ | $100.52M ▲ | $192.5M ▲ | $14.92M ▲ |
| Q2-2025 | $-40.14M ▼ | $-15.94M ▲ | $35.99M ▲ | $2.39M ▼ | $22.7M ▲ | $-21.42M ▲ |
| Q1-2025 | $-34.32M ▲ | $-35.66M ▼ | $-6.47M ▲ | $5.25M ▲ | $-36.66M ▼ | $-46.28M ▼ |
| Q4-2024 | $-65.92M ▼ | $-3.45M ▼ | $-22.21M ▼ | $2.69M ▲ | $-23.11M ▼ | $-12.39M ▼ |
| Q3-2024 | $-30.57M | $10.38M | $10.19M | $100K | $20.76M | $-307K |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 CHINA | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 FRANCE | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $20.00M ▲ |
 GERMANY | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
 International Markets | $50.00M ▲ | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ |
 JAPAN | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 UNITED STATES | $110.00M ▲ | $90.00M ▼ | $90.00M ▲ | $100.00M ▲ |
CEO
Frank Leonard
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 156
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Piper Sandler
Overweight
Wells Fargo
Equal Weight
JP Morgan
Neutral
Wedbush
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:16.77M
Value:$230.92M
BLACKROCK, INC.
Shares:13.95M
Value:$192.06M
BLACKROCK INC.
Shares:12.13M
Value:$167.06M
Summary
Showing Top 3 of 323